Roche Paid $36.5 Million to Screen 300,000 Bispecific Combinations
Roche has not bought a molecule or a target. It has bought a search, and the pairing is an output rather than an input.
DealPulse Signal
The Beats
Analysis
The Briefs
Roche Paid $36.5 Million to Screen 300,000 Bispecific Combinations
Novo’s $1.4 Billion Orbis Deal Does Not Say What It Paid at Signing
NICE Wants Cosmetic Providers to Screen for BDD and Refer Rather Than Operate
ICER Priced Tavapadon Before the FDA Approved It or AbbVie Named a Price
NICE Reversed on Enhertu Because the Threshold Moved, Not the Evidence